News | 12 May 2026
Dr. Reddy’s to participate in HSBC, Bank of America investor conferences
Pharma major to engage with institutional investors through group meetings in Mumbai and Singapore during May 2026
Pharma major to engage with institutional investors through group meetings in Mumbai and Singapore during May 2026
The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year
Proposed amalgamation now awaits NCLT approval; shareholders to receive 51 Torrent Pharma shares for every 100 JB Pharma shares held
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
Expands manufacturing push & locks in major growth deals
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
The acquisition positions Roche more aggressively in digital pathology and precision diagnostics capabilities
Initiative aims to strengthen South-South collaboration and capacity building in biomedical research
Hair care & quick commerce shine
The partnership will focus on diabetes and NCD awareness, rare disease screening, and deployment of mobile medical units
LIR Life is working on a patch-based, transdermal delivery system for GLP-1 therapies targeting obesity
Successful inspection outcome strengthens company’s regulatory compliance and manufacturing standards in China
The deal brings SAI — a key distributor serving pharmaceutical and nutraceutical manufacturers — into the Safic-Alcan Group’s expanding Asia footprint
The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
At the center of the deal is TERN-701, a drug recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for adults with Philadelphia chromosome-positive chronic myeloid leukemia
The standout story remains Wegovy, particularly its new oral formulation
The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
The company informed stock exchanges that the appellate authority has set aside the GST demand along with applicable interest and penalty
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
Subscribe To Our Newsletter & Stay Updated
